Gynecologic Cancer
Report: Lung cancer survival improves, progress stagnates in breast, prostate cancers
An increasing percentage of lung cancer cases are being diagnosed at an earlier stage, according to a new report from American Cancer Society.
FDA clears IND application for allogeneic CAR-T to treat certain solid tumors
The FDA cleared an investigational new drug application for P-MUC1C-ALLO1, a chimeric antigen receptor T-cell therapy designed to treat adults with locally advanced or metastatic epithelial-derived solid tumors.
New NASA radiation exposure limit would bring equality to female, male astronauts
A committee of experts from science, medicine and academia, among other fields, has recommended NASA proceed with a proposal for a universal, career-long radiation dose limit for all astronauts.
Tamoxifen-induced PI3 kinase pathway activation may increase uterine cancer risk
Patients with breast cancer who developed tamoxifen-associated uterine cancer had fewer phosphatidylinositol 3-kinase pathway mutations than those with de novo cases, according to results presented at San Antonio Breast Cancer Symposium.
Cytoreductive surgery before chemotherapy benefits women with recurrent ovarian cancer
Cytoreductive surgery before chemotherapy led to significant and clinically meaningful OS and PFS benefits for women with recurrent ovarian cancer, according to a phase 3 study published in The New England Journal of Medicine.
Mirvetuximab soravtansine active in previously treated ovarian cancer
Mirvetuximab soravtansine induced confirmed objective response in about one-third of women with folate receptor alpha-high platinum-resistant ovarian cancer who previously received bevacizumab, according to the agent’s manufacturer.
FDA approves Cytalux to identify ovarian cancer lesions during surgery
The FDA approved the imaging drug pafolacianine to help surgeons identify ovarian cancer lesions.
Roswell Park appoints chair in gynecologic oncology
Emese Zsiros, MD, PhD, has been promoted to lead the department of gynecologic oncology at Roswell Park Comprehensive Cancer Center.
Most therapies tested in phase 3 cancer trials fail to confer meaningful survival benefit
More than 80% of therapies tested in phase 3 oncology trials did not demonstrate clinically meaningful benefit in extending survival, according to results of a study published in JNCCN — Journal of the National Comprehensive Cancer Network.
Neoadjuvant chemotherapy may be optimal first-line treatment in advanced ovarian cancer
Increased use of neoadjuvant chemotherapy appeared associated with improvements in short-term mortality without sacrificing long-term survival in ovarian cancer, according to a comparative effectiveness research study in JAMA Oncology.